Canonical Wnt signaling coordinates many critical aspects of embryonic development, while dysregulated Wnt signaling contributes to common diseases, including congenital malformations and cancer. The nuclear localization of β-catenin is the defining step in pathway activation. However, despite intensive investigation, the mechanisms regulating β-catenin nuclear transport remain undefined. In a patient with congenital heart disease and heterotaxy, a disorder of left-right patterning, we previously identified the guanine nucleotide exchange factor, RAPGEF5. Here, we demonstrate that RAPGEF5 regulates left-right patterning via Wnt signaling. In particular, RAPGEF5, regulates the nuclear translocation of β-catenin independently of both β-catenin cytoplasmic stabilization and the importin β1/Ran mediated transport system. We propose a model whereby RAPGEF5 activates the nuclear GTPases, Rap1/2, to facilitate the nuclear transport of β-catenin, defining a parallel nuclear transport pathway to Ran. Our results suggest new targets for modulating Wnt signaling in disease states.
INTRODUCTION:
Canonical Wnt signaling is a highly conserved regulatory pathway for many aspects of embryonic development and adult tissue homeostasis. When dysregulated, Wnt signaling contributes to numerous diseases, including congenital malformations, neurodegeneration, diabetes, and multiple cancers (Clevers and Nusse, 2012; MacDonald et al., 2009; Moon et al., 2004; Niehrs, 2012) . In the defining step of the pathway, nuclear translocation of β-catenin is essential. In fact, Wnt ligand binding inhibits the cytoplasmic β-catenin destruction machinery allowing β-catenin to accumulate and enter into the nucleus (MacDonald et al., 2009; Niehrs, 2012) .
However, despite intensive investigation, the regulators of β-catenin nuclear transport have been enigmatic. β-catenin lacks a nuclear localization signal (NLS) and does not require the Ran-GTPase-regulated importin/karyopherin transport carriers to access the nuclear compartment (Fagotto, 2013; Fagotto et al., 1998; Wiechens and Fagotto, 2001; Xu and Massague, 2004; Yokoya et al., 1999) . Nevertheless, there are clear parallels with the Ran based system: 1) translocation of β-catenin occurs through Nuclear Pore Complexes (NPCs), 2) the armadillo (ARM) repeats in β-catenin are structurally similar to the ARM and HEAT repeats found in importin-α and importin-β family members, and β-catenin competes for NPC-binding sites with importin-β1, 3) nuclear import is energy dependent, and 4) import of β-catenin is inhibited by nonhydrolyzable GTP analogs, suggesting the involvement of an unknown GTPase (Fagotto, 2013; Fagotto et al., 1998; Jamieson et al., 2014; Lowe et al., 2015; Xu and Massague, 2004) . Together, these data demonstrate that β-catenin uses a non-classic pathway for nuclear transport; however, the molecular regulators of this process are unknown.
We previously identified the guanine nucleotide exchange factor, RAPGEF5 as a candidate disease gene in a patient with congenital heart disease and heterotaxy (Fakhro et al., 2011) . Heterotaxy is a disorder of left-right (LR) patterning. Normally, our internal organs, such as the heart, are asymmetrically positioned across the LR axis, and patients with heterotaxy can have an especially severe form of congenital heart disease (Brueckner, 2007; Sutherland and Ware, 2009 ). However, no developmental function for RAPGEF5 had been established. Here we show that RAPGEF5, regulates left-right patterning via Wnt signaling. Importantly, RAPGEF5 is critical for the nuclear localization of β-catenin independently of cytoplasmic stabilization and the importin α/β1 mediated transport system. We propose a model whereby RAPGEF5 activates nuclear Raps to facilitate the nuclear transport of β-catenin, identifying new targets for modulating Wnt signaling in disease.
RESULTS:

Rapgef5 is required for left -right development
To investigate whether RAPGEF5 is required for normal left-right development, we first examined organ situs in Rapgef5 depleted Xenopus embryos. The frog model, Xenopus, is ideal for these studies as both gain and loss of function experiments are rapid and efficient; for example, three days after manipulating fertilized Xenopus eggs, we can readily assess cardiac situs by simple inspection of Xenopus tadpoles (Blum et al., 2009) . In vertebrates, the developing cardiac tube initially forms in the midline and then normally loops to the right (D-loop). However, defects in left-right patterning result in morphological abnormalities, including leftward (L) or ambiguous (A) loops (Brueckner, 2007; Sutherland and Ware, 2009 ). Knockdown of rapgef5 using translation (R5 MO ATG ) or splice (R5 MO Splice ) blocking morpholino oligonucleotides (MOs), as well as CRISPR mediated F0 depletion (Bhattacharya et al., 2015) , resulted in abnormal cardiac looping and confirmed a role for Rapgef5 in left-right development (Fig. 1A) . The efficacy and specificity of these knockdown strategies was confirmed by RT-PCR, western blot and RNA rescue (Fig. S1 ).
Left-right symmetry is first broken at the left-right organizer (LRO). Here motile cilia generate a leftward fluid flow that is detected by laterally positioned immotile sensory cilia and translated into asymmetric gene expression (Boskovski et al., 2013; Kennedy et al., 2007; McGrath et al., 2003; Tabin and Vogan, 2003; Yoshiba and Hamada, 2014) . In particular, leftward flow results in the asymmetric expression of coco (dand5, cerl2) in the LRO, and subsequent activation of TGF-β family members and pitx2c expression in the left lateral plate mesoderm (Kawasumi et al., 2011; Logan et al., 1998; Schweickert et al., 2010; Vonica and Brivanlou, 2007) . Knockdown of Rapgef5 resulted in abnormalities in both pitx2c and coco expression demonstrating that rapgef5 is required at the level of the LRO (Fig. 1B-D) . Importantly in the LRO, coco expression is normally symmetric prior to cilia driven flow (Schweickert et al., 2010) ( Fig. 1D , far left panel, Stage (st) 16); however, in morphants coco expression was reduced even at these pre-flow stages (st 16, Fig. 1D ), suggesting a defect in the establishment of the LRO itself. This was confirmed by assaying expression of additional LRO marker genes, xnr1 and gdf3 (Vonica and Brivanlou, 2007) , both of which were reduced before initiation of flow in morphants (Fig. 1E) . Thus, Rapgef5 is required for correct establishment of the LRO and subsequent L-R development.
Depletion of Rapgef5 impairs canonical Wnt signaling
As the LRO fails to form normally in rapgef5 morphants, we next examined the preceding development of this structure. The Spemann organizer forms at the dorsal blastopore lip and serves to pattern dorsal structures, including the LRO (De Robertis et al., 2000; Harland and Gerhart, 1997; Khokha et al., 2005; Niehrs, 2004) . There, we discovered that foxj1 and xnr3 transcripts, known direct targets of Wnt signaling (Caron et al., 2012; McKendry et al., 1997; Smith et al., 1995; Stubbs et al., 2008; Walentek et al., 2012) , were reduced in gastrulating rapgef5 morphants ( Fig. 2A) . On the other hand, numerous additional dorsal, ventral and pan-mesodermal markers were unaffected (Fig.   S2 ). Importantly, co-injection of human RAPGEF5 mRNA rescued the foxj1 patterning defect, demonstrating the specificity of our MO knockdown (Fig. S1D) . Based on the reduction of foxj1 and xnr3 expression in rapgef5 morphants, we hypothesized that Rapgef5 may play a role in Wnt signaling.
Wnt signaling plays diverse roles in embryonic development, including formation of primary axes, as well as in common human diseases such as cancer (Clevers and Nusse, 2012; Jamieson et al., 2014; MacDonald et al., 2009; Moon et al., 2004; Niehrs, 2012; Yamaguchi, 2001) . β-catenin plays a central role in the canonical Wnt pathway (Fagotto et al., 1997; Funayama et al., 1995; Heasman et al., 1994; McCrea et al., 1993) . In the absence of Wnt ligand, cytoplasmic β-catenin is phosphorylated and marked for degradation by a highly efficient destruction complex consisting of GSK3, CK1, APC and Axin (Clevers and Nusse, 2012; Davidson et al., 2005; Kofron et al., 2007; MacDonald et al., 2009; Niehrs, 2012; Taelman et al., 2010) . This destruction complex maintains cytoplasmic β-catenin at low levels so that it cannot accumulate in the nucleus, repressing canonical Wnt signaling (Fig. 2B) . When the Wnt ligand binds to the Frizzled receptor and the LRP6 co-receptor, the destruction complex is inactivated, and β-catenin accumulates and translocates into the nucleus to induce transcription of Wnt target genes (Bhanot et al., 1996; Davidson et al., 2005; Fagotto et al., 1997; Funayama et al., 1995; He et al., 1997; Heasman et al., 1994; MacDonald et al., 2009; Mao et al., 2001a; Mao et al., 2001b; Niehrs, 2012; Pinson et al., 2000; Tamai et al., 2000; Yang-Snyder et al., 1996) (Fig. 2B) . Therefore, we began our analysis of the Wnt pathway by examining β-catenin protein levels from whole embryo lysates in rapgef5 morphants. By western blot, β-catenin protein levels are reduced in rapgef5 morphants at stages 10 and 12 compared to uninjected controls (Fig. 2C,D) . Conversely, β-catenin levels were increased by overexpression of human RAPGEF5 (Fig. 2D) . Importantly, while levels of total β-catenin were mildly affected, the active (unphosphorylated) pool of β-catenin that translocates into the nucleus was much more severely affected ( Fig.   2C ,D). Together these observations lead us to postulate that Rapgef5 may be required for the cytoplasmic stabilization of β-catenin.
Rapgef5 acts downstream of cytoplasmic stabilization
To test whether Rapgef5 functions in cytoplasmic stabilization, we first asked if Rapgef5 depletion could counteract the activity of wild type (WT) and stabilized (ST) β-catenin proteins. The degradation machinery phosphorylates β-catenin at specific serine/threonine residues via GSK3; modification of these residues to alanine (S33A, S37A, T41A) prevents phosphorylation and produces a "stabilized" form of β-catenin that evades the degradation machinery (Taelman et al., 2010) . Overexpression of β-catenin can induce a second embryonic axis in Xenopus embryos, which can be easily scored by simple inspection (Fig. 3A, left panel) . Co-injection of either rapgef5 MO or GSK3 mRNA significantly reduces the ability of WT β-catenin mRNA to induce secondary axes in Xenopus embryos (Fig. 3A) , suggesting that Rapgef5 acts at the level of β-catenin signaling rather than upstream in the pathway. As expected, coinjection of GSK3 mRNA has no effect on the ability of stabilized β-catenin to induce a secondary axis. However, surprisingly, co-injection of rapgef5 MO did reduce the ability of stabilized β-catenin to induce secondary axes (Fig. 3A) suggesting that Rapgef5 acts independently of β-catenin stabilization.
An alternative method to assay Wnt signaling, TOPFlash luciferase assays place luciferase expression under the control of TCF/LEF binding sites (Molenaar et al., 1996; Veeman et al., 2003) . In this case, activation of Wnt signaling leads to the accumulation of nuclear β-catenin that complexes with TCF/LEF to activate luciferase expression.
Consistent with our induced secondary axis experiments, Rapgef5 depletion reduced the luciferase signal of both WT and stabilized β-catenin in TOPFlash assays in Xenopus embryos (Fig. 3B) . To see if this result was conserved to mammals, we depleted Rapgef5 using siRNAs in primary mouse embryonic fibroblasts. In mice, the specific serine/threonine residues that are phosphorylated by GSK-3 and lead to degradation of β-catenin are encoded on a single exon. Excision of this exon creates cells that express a genetically stabilized β-catenin allele (Harada et al., 1999) . Even in cells with the stabilized β-catenin allele, depletion of Rapgef5 led to decreased luciferase activity (Fig. 3C ).
To further test whether Rapgef5 regulates Wnt signaling independently of β-catenin degradation, we pursued a parallel strategy to inhibit GSK3 activity pharmacologically using the chemical inhibitor BIO (Sato et al., 2004) . Wnt signaling must be attenuated to form the head (Glinka et al., 1998; Yamaguchi, 2001) , so activation of Wnt signaling with BIO between stages 9 and 12 leads to a dramatic reduction in head development. Knockdown of rapgef5 using either R5 MO ATG or R5 MO Splice could counteract the effect of BIO and rescue development of the head (Fig.   3D ). Taken together in both frogs and mammals, these studies indicate that Rapgef5
regulates Wnt signaling independently of the well-established β-catenin cytoplasmic destruction machinery, suggesting that Rapgef5 acts downstream in the Wnt signaling pathway (Fig. 1B) .
Nuclear translocation of β-catenin is impaired in rapgef5 morphants
Our initial experiments with whole embryo lysates indicated that β-catenin levels were lower with Rapgef5 depletion (Fig. 2C,D) ; therefore, we had initially hypothesized that Rapgef5 plays a role in β-catenin degradation. Given the results described above, we sought alternative explanations and began with studies to examine β-catenin localization. To directly visualize β-catenin, we injected GFP tagged WT and stabilized β-catenin mRNA at the one cell stage and imaged the dorsal blastopore lip at stage 10.
Concurrently, to enable ratiometric analysis with an importin-β1 transported cargo, we co-injected mCherry tagged with a N-terminal classic nuclear localization signal from SV40 large T antigen ("PKKKRKV"; NLS-mCherry). In control embryos, the GFP tagged β-catenin localized robustly to dorsal nuclei and the plasma membrane; however, levels of nuclear β-catenin were significantly diminished in rapgef5 morphants whether we used the WT or stabilized variant of β-catenin. We examined this result in two ways.
First, we compared GFP and RFP signals in the cytoplasm compared to the nucleus. In both WT β-catenin-GFP and stabilized β-catenin-GFP injected embryos, the nuclear:cytoplasmic ratio of β-catenin was reduced with depletion of Rapgef5 while no effect was observed with the NLS-mCherry (Fig. 4A ,B far right panels). Second, we compared the nuclear signal from β-catenin (green channel) to nuclear signal of NLSmCherry (red) and observed a reduction in the β-catenin/mCherry ratio in Rapgef5 depleted embryos (Fig. 4A ,B middle panels).
We noted in these experiments that our NLS-mCherry faithfully localizes to the nucleus even when Rapgef5 is depleted and β-catenin nuclear localization is impaired.
We wondered if adding the NLS signal from SV40 to β-catenin might "rescue" the nuclear localization phenotype in embryos depleted of Rapgef5. In both the secondary axis assay (Fig. 3A ) and the visualization of GFP signal (Fig. 4C ), addition of a classic NLS signal to β-catenin makes it insensitive to Rapgef5 depletion. Taken together, depletion of Rapgef5 has little effect on the Ran/importin-β1 nuclear transport pathway which can rescue β-catenin nuclear translocation upon the addition of a classic NLSsignal. Therefore, Rapgef5 may define a parallel nuclear transport system that is critical for β-catenin.
We next sought to evaluate β-catenin cellular compartmentalization without overexpression. We fractionated the nucleus and cytoplasm and examined the levels of β-catenin by Western blot (Fig. 5) . In wild type Xenopus embryos at stage 10, β-catenin is present in both nuclear and the cytoplasmic/plasma membrane fractions (where it plays a critical role in cell adhesion (Brembeck et al., 2006) (Fig. 5A) . In rapgef5 morphants, levels of β-catenin were significantly reduced in the nucleus despite a relatively minor reduction in the cytoplasm (Fig. 5A,C) . If we treat the embryos with the GSK-3 inhibitor, BIO, and normalize the intensities of β-catenin to control embryos without BIO treatment, inhibition of the degradation machinery increases the amount of β-catenin in both the cytoplasmic and nuclear fractions (Fig. 5B,C) . However, when we deplete Rapgef5, the amount of β-catenin in the nucleus is substantially reduced despite there being more cytoplasmic β-catenin than in wildtype embryos (Fig. 5C ).
From these studies, we conclude that rapgef5 depletion inhibits the nuclear localization of β-catenin even if the cytoplasmic levels of β-catenin are high due to inhibition of the cytoplasmic destruction machinery.
A Rapgef5 centered nuclear translocation system
If rapgef5 regulates nuclear translocation of β-catenin, then its expression and activity must be consistent with a role at this location. We first examined its developmental expression pattern and subcellular localization. Using anti-sense mRNA in situ hybridization, we find that both Rapgef5 and isoforms of its target GTPases, Rap1 and Rap2 (Quilliam et al., 2002; Rebhun et al., 2000) , are expressed in multiple tissues throughout development, including the blastopore lip and LRO (Fig. S3 ). By immunohistochemistry, Rapgef5 protein is localized specifically to the nuclei of both whole mount and paraffin sectioned wild type Xenopus embryos at stages 10 and 28
( Fig. S4A ) and was reduced in rapgef5 morphants ( Fig. S4A panel 2,3 ). Rapgef5 is also localized to the nuclei of human RPE cells and mouse embryonic fibroblasts suggesting an evolutionary conserved nuclear function (Fig. S4B,C) . Consistent with previously documented roles in cell adhesion and migration (Caron, 2003) , the isoforms of Rapgef5's target Rap proteins localize near the plasma membrane as well as the cytoplasm based on immunohistochemistry or expression of fluorescently tagged proteins ( Fig. S4D) . Intriguingly, Rap1B, Rap2A and Rap2B also localize to the nucleus, while Rap1A accumulated in a reticular pattern that encompasses the perinuclear region suggesting a distribution throughout the nuclear envelope and ER (Fig. S4D ).
These results suggest an evolutionary conserved nuclear RAP system.
Based on their nuclear localization and previously reported biochemical activity (de Rooij et al., 2000; Quilliam et al., 2002; Rebhun et al., 2000) , we propose a working model whereby Rapgef5 maintains nuclear Rap proteins in their active GTP bound state, which is crucial for the nuclear translocation of β-catenin. Indeed, previous reports have suggested that Rap1 localizes to the nucleus, influences nuclear β-catenin levels, and alters gene transcription profiles (Bivona and Philips, 2005; Lafuente et al., 2007) .
As a preliminary test of this model, we asked if nuclear Raps are in their active GTP bound conformation. GFP-RBD RalGDS is an active Rap sensor, consisting of the Ras binding domain of RalGDS fused to GFP, and binds specifically to the active form of Rap1-GTP and Rap2-GTP but not the inactive GDP form to allow visualization of subcellular localization (Bivona and Philips, 2005; Liu et al., 2010) . In addition to previously described signals at the plasma membrane, we confirmed high levels of active Raps within Xenopus nuclei (Fig. 6A ). Our model would also suggest that active Raps and β-catenin physically interact. In support of this, we found that Rap1 coimmunoprecipitated with β-catenin, and importantly that β-catenin is pulled down specifically with RBD RalGDS, indicating that active Rap1/2 binds β-catenin in stage 10
Xenopus embryos (Fig. 6B,C) , results consistent with a previous report in human cancer cell lines (Goto et al., 2010) . Taken together, we conclude 1) Rapgef5 and multiple Rap proteins localize to the nucleus, 2) at least a subset of the Raps in the nucleus are in the active GTP form, and 3) active Rap proteins physically interact with β-catenin.
DISCUSSION:
Integrating the sum of our data, we develop a model where RAPGEF5 activates nuclear Raps, which are necessary for the translocation of β-catenin to the nucleus. This model parallels the classic Ran based transport system, which maintains a nuclear pool of Ran-GTP through the activity of a chromatin-bound Ran-GEF, RCC1 (Kutay et al., 1997; Lange et al., 2007; Lowe et al., 2015; Xu and Massague, 2004) . Structurally, β-catenin's 12 Arm repeats are similar to the HEAT repeats found on importin-β family members suggesting that it might directly interact with the FG-nups of the NPC central channel (Fagotto, 2013; Xu and Massague, 2004) . Consistent with this idea, importin-β1
can inhibit the translocation of β-catenin into the nucleus suggesting competition for NPC binding sites (Fagotto, 2013; Fagotto et al., 1998; Kutay et al., 1997; Xu and Massague, 2004) . Finally, like the Ran based transport system, β-catenin's nuclear translocation is energy dependent and depletion of ATP/GTP or addition of nonhydrolyzable GTP analogs (Fagotto et al., 1998) inhibits nuclear import, suggesting the involvement of a GTPase.
However, β-catenin nuclear import is independent of the Ran based transport system, and the identity of the GTPase is unknown. We propose that the requirement of RAPGEF5 for β-catenin nuclear translocation implicates a Rap GTPase in this role ( Fig.   6D ). Supporting this idea is our observation that addition of a classic NLS signal to β-catenin decouples β-catenin import from Rapgef5 and allows it to use the importin/Ran system for nuclear translocation. Also, active Raps are able to bind β-catenin and are located in the nucleus. Elucidating the precise mechanism requires further study and additional differences with the Ran based transport system may be discovered.
Currently, whether Rapgef5 activity contributes to the translocation of β-catenin through NPCs or functions in a pathway that mediates β-catenin retention in the nucleus remains uncertain (Fig. 6D ). Additionally, Ran-GTP acts to release karyopherin/importins from their NLS-bearing cargos; whether a β-catenin cargo is present or not remains to be seen. Importantly, Rapgef5 is localized to the nuclei of all examined cells in the embryo suggesting that its role in cell signaling is equally broad.
Further studies will need to address whether the function of Rapgef5 is restricted to β-catenin or if it also effects the nuclear localization of other ARM repeat bearing proteins that lack an NLS, such as APC, p120 catenin, and Smad2.
We began our studies investigating a disease candidate gene identified in a patient with Heterotaxy and congenital heart disease. By using our high-throughput animal model, Xenopus, we identified an LR patterning defect in Rapgef5 depleted embryos, and given our desire to understand the pathophysiology of our patient, we discovered a novel role of Rapgef5 in the nuclear localization of β-catenin, an essential step in the 
STAR METHODS:
Contact for Reagent and Resource Sharing
Further information and requests for reagents may be directed to, and will be fulfilled by the corresponding author Mustafa K. Khokha (mustafa.khokha@yale.edu)
Experimental Model and Subject Details
Xenopus X. tropicalis were maintained and cared for in our aquatics facility, in accordance with Yale University Institutional Animal Care and Use Committee protocols. Embryos were produced by in vitro fertilization and raised to appropriate stages in 1/9MR + gentamycin as per standard protocols (del Viso and Khokha, 2012).
Mice
Production of the mouse Catnblox(ex3) allele, carrying a loxP flanked β-catenin exon 3, was as previously described (Harada et al., 1999 
Method Details
Morpholino oligonucleotides, mRNA and CRISPRs
Injections of Xenopus embryos were carried out at the one-cell stage as previously described (Khokha et al., 2002) . We obtained ATG blocking (R5 MO ATG , 5' -CTTTAAAAGTCTGACACCCATGAGC-3') or splice blocking (R5 MO Splice , 5' -GCCTAAGGAAAAACTCTTACCTCCA -3') morpholino oligonucleotides from Gene Tools LLC and injected 8ng at the one cell stage to deplete Rapgef5. CRISPR sgRNAs containing the following rapgef5 target sequences (5' -GGACTTCCTTCTCACATACA -3' and 5' -GGGGACCCCGGAAAAGATTC -3') were designed from the v7.1 model of the Xenopus genome. sgRNAs and Cas9 protein was used to genetically knockdown rapgef5 in F0 embryos as previously described (Bhattacharya et al., 2015) . Full length human RAPGEF5 (clone HsCD00511998) was subcloned into the pCSDest2 vector using Gateway recombination techniques. Capped mRNAs were generated in vitro using the mMessage machine kit (Ambion) following the manufacturer's instructions. β-catenin-GFP (Addgene #16839), Stabilized β-catenin-GFP (Addgene #29684), NLS β- 
RT-PCR
The R5 MO Splice morpholino was targeted to the splice donor site in intron 2 of rapgef5.
Retention of intron 2 was confirmed by RT-PCR, using the following primers: Forward:5' TCCACTGTACAAGTGAAGGAAGA 3', reverse: 5' TGTCTTGTACCTCATCCAGG 3'.
In Situ Hybridization
Digoxigenin-labeled antisense probes for chordin: Tneu011C22, coco: TEgg007d24, fgf8: Tneu007i10, foxj1: Tneu058M03, gdf3: Tgas137g21, gsc: TNeu077f20, noggin:
TNeu122a14, not; TEgg044k18, otx2; TGas114a06, pitx2; TNeu083k20, Rap1A:
TEgg114f09, Rap2A: TGas143d22, Rap2B; TGas123a15, t; TGas116l23, rapgef5;
IMAGE:6494175, vent; TNeu119b08, xnr1 TGas124h10, and xnr3; Tgas011k18 were in vitro transcribed with T7 High Yield RNA Synthesis Kit (E2040S) from New England Biolabs. Embryos were collected at the desired stages, fixed in MEMFA for 1-2 hours at room temperature and dehydrated into 100% ETOH. Whole mount in situ hybridization was performed as described previously (Khokha et al., 2002) .
Immunofluorescence
Xenopus embryos and mammalian cells were collected at desired time points and fixed in 4% paraformaldehyde/PBS (Xenopus = overnight (ON) at 4 o C, cells = 15 mins at RT).
Stage 10 Xenopus embryos were also embedded in paraffin and cut into 10 µm confocal microscope. Image analysis was carried out using ImageJ.
Pharmacological inhibition of Gsk3
To inhibit GSK3α/β function during anterior development in WT Xenopus embryos and morphants, 6-bromoindirubin-3′-oxime (BIO, Sigma-Aldrich B1686) was added to the media at a concentration of 10 µM between stages 8 and 11. Media was then changed and the embryos allowed to develop. Anterior development was scored as normal, Nuclear/cytoplasmic protein fractionation Pools of 30 embryos were collected at stage 10 for each treatment including controls in eppendorf tubes, (a maximium of 35 and minimum of 20 embryos can be used with the solution volumes outlined in this protocol, but the protein concentrations will vary). All centrifugation steps were done at 4 o C. 1 ml of Buffer E1 (see below for details for E1, E2, E3) was added to the embryos, and they were homogenized using a pipette.
Lysates were centrifuged at 13,000 rpm at 4 o C for 5 min. Approximately 600-650 µl of the supernatant was transferred to a new eppendorf tube (avoiding the lipid fraction) and placed on ice (cytoplasmic fraction). The remaining supernatant was discarded, and any lipids were removed from the tube walls using a Kimwipe, talking care not to disturb the pellet (nuclear fraction).
The nuclear and cytoplasmic fractions were then purified. For the cytoplasmic fraction, 11 µl of buffer CERII from the NE-PER Nuclear and Cytoplasmic Extraction
Reagents Kit (Thermo-Scientific #78833) was added and tubes were vortexed for 15 sec, incubated on ice for 5 min and centrifuged for another 5 min. The supernatant (~ 500 µl) was transferred to a clean tube again avoiding lipid contamination. This cytoplasmic fraction was stored at -80 o C until use.
The nuclear fraction pellet was resuspended in 1 ml of buffer E1 by pipetting (some material might remain insoluble), incubating on ice for 5 min and centrifuging for 5 min.
The supernatant was discarded following centrifugation and any lipids were removed using Kimwipes without touching the pellet. This washing step was then repeated. After the second centrifugation the pellet was resuspended in 1 ml of buffer E2 and centrifuged for 5 min. The supernatant was discarded. This step was repeated once.
Subsequently, the nuclear pellet was resuspended in 500 µl of buffer E3 and centrifuged for 5 min. The supernatant was discarded and the pellet was finally resuspended in 150 µl of Buffer E3. This is the nuclear fraction.
Protein concentrations of the nuclear and cytoplasmic fractions were determined using DC Protein Assay (Biorad # 5000112). Protein fractions were stored at -80 o C. All buffers were supplemented with proteinase inhibitor (Complete, Roche # 11697498001) and PMSF (0.2 mM final concentration) prior to use. Buffer E1 was also supplemented with DTT (1 mM final concentration).
Buffer compositions: Buffer E1: 50 mM HEPES-KOH, 140 mM mL NaCl, 1 mM EDTA (pH 8.0), 10% Glycerol (v/v), 0.5% Igepal CA-630 (v/v), 0.25% Triton X-100 (v/v).
Buffer E2: 10 mM Tris-HCl (pH 8.0), 200 mM NaCl, 1 mM EDTA (pH 8.0), 0.5 mM
Quantification and Statistical Analysis
For Figure 1 , the in situ results were analyzed by chi-squared test or Fishers exact test as appropriate for sample size. In Figure 2 the double axis assay data was examined using fishers exact test, the BIO treatment by Chi-squared and the TOPFlash by t-test. For Figure 3 and Extended Data 3, a t-test (two-tailed, type two) was used to determine significance of the ratiometric analysis, and the western blot data was analyzed by Anova Sidak. In Extended Data 2 fishers exact test was used to analyze the in situ data. Note that levels of active β-catenin are much more severely affected. Conversely, over expression of human RAPGEF5 mRNA results in a mild increase in total β-catenin levels and a more pronounced increase in active β-catenin levels. A triple asterisks indicates P<0.005. GFP tagged WT and ST β-catenin localize to the plasma membrane and nucleus in the dorsal blastopore lip of control embryos but this nuclear localization is lost in rapgef5 morphants (note loss of nuclear GFP signal in merged images). (C) NLS β-catenin-GFP localizes normally into nuclei even in the absence of Rapgef5. Graphs in the center panel represent the ratio of nuclear localized GFP relative to NLS-Cherry control (Data are represented as mean ± SEM). The graphs on the right display ratiometric analysis of nuclear vs cytoplasmic GFP (β-catenin) and NLS-mCherry levels. Nuclear localized β-catenin is reduced in Rapgef5 morphants relative to controls at stage 10 for WT and stabilized β-catenin but not NLS-β-catenin. Localization of NLS-mCherry is unaltered. Graphs represent mean ± SEM. A single asterisk indicates P<0.05. (A) Nuclear/cytoplasmic fractionation reveals that levels of endogenous β-catenin are reduced in the nuclei of Rapgef5 morphants, while cytoplasmic levels are essentially normal. (B) BIO treatment does not rescue the nuclear localization of endogenous β-catenin. (C) Quantification of average β-catenin levels in nuclear and cytoplasmic fractions of control and morphant embryos with or without BIO treatment (error bars represent S.E.M.). All nuclear treatments (black bars) are relativized to the BIO untreated nuclear control and all cytoplasmic treatments (grey bars) are relativized to the BIO untreated cytoplasmic control. Note the reduction of nuclear localized β-catenin in Rapgef5 depleted embryos with or without BIO treatment. The BIO treated rapgef5 morphants have less nuclear localized β-catenin than BIO untreated UC controls, despite having higher levels of cytoplasmic β-catenin. A single asterisk indicates P<0.05. (gsc, chordin, fgf8, otx2, vent, t, not and noggin) are not affected at stage 10 by depletion of Rapgef5. Vegetal views with dorsal to the top. Figure S3 . Related to Fig. 6 ; Developmental expression of Rapgef5 and Rap genes. In situ hybridization reveals rapgef5 mRNA is present from the earliest stages of development. It is detected in the animal pole at the 2 cell and 8 cell stages. In the stage 10 embryos expression appears diffuse around the blastopore. At stage 14 transcripts are detected in the anterior neural folds and forming GRP. rapgef5 expression is restricted to the anterior neural tube, brain, pharyngeal arches and cranial placodes at stage 28. Rap1A, Rap2A and Rap2B are all expressed in the 4 cell embryo, in the gastrulating stage 10 embryo and in the GRP at stage 16. Expression of all three genes is also strong in the neural folds at stage 16, while Rap2B also displays an interesting speckled pattern on the lateral ectoderm. All three are expressed in the neural tube, brain, eye and pharyngeal arches at stage 28. 
